Our network has expanded. PCRN have joined us and rebranded to Momentum Clinical Research.
- Home
- Clinical Trials
Healthy volunteers studies Auckland (1)
Hebe Healthy Volunteers Study Auckland
Auckland
We are looking for healthy volunteers aged 18 to 65 for a Phase 1 clinical research study of ZL-1503, an investigational medicine being developed for moderate-to-severe atopic dermatitis. The study will evaluate how the body processes ZL-1503 and assess its safety and tolerability following a single dose.
Participating may help advance clinical research. There may be no direct health benefit to you from taking part.
Description
What to expect
Study details
Ages
18-65
Duration
The study duration is up to 52 weeks, including a screening period of up to 28 days, a single dosing day, and follow-up appointments through to Day 337. Participation includes a screening visit, an inpatient stay from Day -1 through completion of Day 4 assessments, and around 11 outpatient follow-up visits.
Compensation
Participants will be paid for time and study-related costs.
Eligibility Criteria
You may qualify for this study if you:
- Are male or female and aged 18 to 65 years
- Are healthy based on medical history, physical examination, ECG, vital signs and screening laboratory tests
- Have a body mass index (BMI) of at least 18.5 and less than 32.5 kg/m²
- Weigh at least 45 kg and no more than 100 kg
- Are willing and able to comply with study requirements, including contraception requirements where applicable
- Are willing and able to stay four nights at our clinic facility
Other criteria may apply.
Locations
Description
ZL-1503 is an investigational antibody being developed as a potential future medicine for moderate-to-severe atopic dermatitis. Atopic dermatitis is a chronic skin condition that can involve itch, skin lesions, discomfort and reduced quality of life.
This study is being conducted in healthy volunteers to evaluate the pharmacokinetics, safety, tolerability and immune response to ZL-1503 after one subcutaneous or intravenous dose.
Please note, our next admission dates for this study are as follows:
- Cohort 2B | 28 September 2026
- Cohort 3A | 29 September 2026
- Cohort 3B | 11 October 2026
What to expect
If you choose to take part and are eligible, you will be randomly assigned to receive a single dose of ZL-1503 by either intravenous infusion or subcutaneous injection. Study assessments will include informed consent, medical history, physical examinations, vital signs, ECGs, pregnancy testing where applicable, blood and urine tests, pharmacokinetic and immunogenicity blood sampling, and monitoring for side effects. You will stay at the clinical research unit from the day before dosing through Day 4 assessments and then return for follow-up visits up to Day 337.
Apply now
Fill out your details, and our team will be in touch to discuss your potential involvement in this study and answer any questions you may have.
Momentum Clinical Research NZ is a member of the Global Site Holdings Group. Global Site Holdings Pty Limited ACN 668 977 062 trading as Momentum Clinical Research ABN 51 668 977 062 and our related entities (we, us, our), will use the Personal Information you have provided in the above form to review and respond to your enquiry, to contact you about any future trials or studies you may be eligible for, and otherwise in accordance with our Privacy Policy and as required and authorised by law. We may not be able to provide you with a complete response or a response at all to your enquiry if you do not provide the requested information. By clicking 'Submit' you agree to our Privacy Policy which contains further information about how we collect, use, store or disclose your Personal Information, how you may seek access and correction of your Personal Information, and how you may make a complaint about a breach of privacy. If you have questions, please contact us at contact@momentumclinicalresearch.com.